Business
Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026
Completed enrollment in DENALI Part 2a; dose confirmation expected in 1H 2026DENALI Part 2 trial topline readout expected by year end 2026; potential to support accelerated approvalInitiation of the ASPENOVA Phase 3, randomized, confirmatory trial planned in 1H 2026 SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-d
About this update from Zentalis Pharmaceuticals, Inc.
[{"type":"image","alt":"ZENTALIS PHARMACEUTICALS","displaySize":"","headline":null,"caption":"ZENTALIS PHARMACEUTICALS","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":87,"url":"https://media.zenfs.com/en/globenewswire.com/8a2329194a3b92e9d92b6dddf1b01631"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nQzP_GawPdWO8YMImzkdkg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8a2329194a3b92e9d92b6dddf1b01631","width":300,"height":87}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Completed enrollment in DENALI Part 2a; dose confirmation expected in 1H 2026","length":77,"tagName":"p"}]},{"val":[{"type":"text","content":"DENALI Part 2 trial topline readout expected by year end 2026; potential to support accelerated approval","length":104,"tagName":"p"}]},{"val":[{"type":"text","content":"Initiation of the ASPENOVA Phase 3, randomized, confirmatory trial planned in 1H 2026","length":85,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":266,"olType":false},{"type":"text","content":"SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today provided a corporate update and highlighted key milestones and expected momentum in the azenosertib development program for 2026.","length":413,"tagName":"p"},{"type":"text","content":""2026 represents a pivotal year for Zentalis as we advance azenosertib toward potential approval in Cyclin E1-positive platinum-resistant ovarian cancer (PROC) and continue to assess its role in additional indications," said Julie Eastland, Chief Executive Officer of Zentalis. "The completion of DENALI Part 2a enrollment marks significant progress, positioning us for dose confirmation in the first half of 2026, followed by an expected topline readout by year end that could support accelerated approval, subject to FDA feedback. Equally important, we expect to initiate ASPENOVA, our randomized Phase 3 confirmatory trial in the first half of 2026, evaluating azenosertib vs. standard-of-care chemotherapy in this biomarker-selected population. Beyond the Cyclin E1-positive PROC setting, this...